Oncology Podcasts | pharmaphorum

Podcasts

Oncology

ESMO26: Taiho Oncology on improving the lives of patients wi...

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

pharmaphorum podcast Episode 276, Irina Babina, Concr

Getting predictive technologies to patients, with Concr

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

Oncology

pharmaphorum podcast Episode 265, Leonard Mazur, Citius

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

ESMO26: Taiho Oncology on improving the lives of patients wi...

ESMO26: Lowering toxicity, extending lives, with Syncromune

Getting predictive technologies to patients, with Concr

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Collaboration & personalisation in rare disease R&D, with AO...

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

Podcasts

Editor's Picks